BUNIA, DEMOCRATIC REPUBLIC OF THE CONGO / RankWire.AI / – The World Health Organization reports that 80% of recent Ebola infections in eastern Congo originate from unidentified transmission chains. The majority of patients initially did not appear on contact tracing lists prior to their infections being confirmed through testing. This gap hampers early isolation efforts and delays treatment for symptomatic individuals. Often, health teams only identify new clusters after patients present at clinics or succumb in their communities. The outbreak involves the less common Bundibugyo virus strain.
As of July 13, Congo had documented 2,011 confirmed cases and 754 deaths. The province of Ituri remained the epicenter, with 1,808 cases and 631 fatalities. North Kivu reported 182 cases with 106 deaths. Other affected regions include South Kivu, Haut-Uele, and Tshopo. Authorities listed 753 patients currently in isolation and 366 recoveries. Response teams are monitoring approximately 67% of contacts identified in the most affected areas.
Contact tracing is vital for identifying exposed individuals before they further spread the virus. Usually, contacts are monitored for 21 days following the last known exposure. WHO stated that 92.3% of 430 investigated deaths up to July 5 happened outside healthcare facilities or prior to hospital admission. These fatalities reduce chances for timely testing and isolation. Ebola transmits through direct contact with contaminated blood or bodily fluids, and contaminated objects can also serve as transmission sources.
Five provinces report confirmed cases
The outbreak has affected 45 health zones across five Congolese provinces. In Ituri, cases have been reported in 26 zones, while North Kivu has 11 zones with infections. Haut-Uele reported 14 cases resulting in 13 deaths. Tshopo documented four cases and three deaths. South Kivu has three cases and a single death. The widespread geographic distribution has increased the burden on laboratories, treatment facilities, and mobile surveillance units.
By July 14, Uganda confirmed 20 cases and two deaths. Seventeen of these patients had recovered, with the most recent confirmed case recorded on June 21. Fifteen infections were linked to travel from Congo, while five involved local transmission. Ugandan health authorities found no evidence of community-wide spread. They also monitored travelers and aid workers leaving affected zones during the outbreak.
Expansion of testing and clinical interventions
There is currently no licensed vaccine or approved treatment specifically targeting Bundibugyo virus. Medical teams are providing supportive care, including fluids, oxygen, and electrolyte replacement. On July 2, WHO added the first molecular diagnostic test for this virus to its Emergency Use Listing. Presently, ten laboratories are supporting testing efforts across the affected region, with a combined capacity of over 2,000 tests daily. Researchers have also initiated a clinical trial involving remdesivir and the antibody therapy MBP134.
The government of Congo, WHO, and Africa CDC are working together to coordinate surveillance, testing, treatment, safe burials, and community outreach efforts. Challenges such as insecurity, displacement, and frequent movement in mining areas hinder access to some communities. Strikes among health workers have also disrupted parts of the response. WHO has received approximately 40% of its $115 million funding appeal. Efforts remain focused on accelerating case detection, as most new infections occur outside known transmission chains.